GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Forward PE Ratio

Virax Biolabs Group (Virax Biolabs Group) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Forward PE Ratio?

Virax Biolabs Group's Forward PE Ratio for today is 0.00.

Virax Biolabs Group's PE Ratio without NRI for today is 0.00.

Virax Biolabs Group's PE Ratio for today is 0.00.


Virax Biolabs Group Forward PE Ratio Historical Data

The historical data trend for Virax Biolabs Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Forward PE Ratio Chart

Virax Biolabs Group Annual Data
Trend
Forward PE Ratio

Virax Biolabs Group Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Virax Biolabs Group's Forward PE Ratio

For the Biotechnology subindustry, Virax Biolabs Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Forward PE Ratio falls into.



Virax Biolabs Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Virax Biolabs Group  (NAS:VRAX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Virax Biolabs Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.